| 摘要 |
Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO: 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Cla16), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGT-GSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion. |
| 主权项 |
1. A composition of matter, said composition of matter selected from the group consisting of:
(i) a polypeptide, or a pharmaceutically acceptable salt thereof, which is up to 30 amino acids in length and comprises:
(I) the amino acid sequence:(a)GGYKAAVRPTMLE,(SEQ ID NO: 35; Cla35)(b)AEVYQKLKSLTKK,(SEQ ID NO: 31; Cla16)(c)VAITYASRAQGAE,(SEQ ID NO: 32; Cla25)(d)GHHFKERGTGSLVIT,(SEQ ID NO: 33; Cla26)or(e)ANYTQTKTVSIRL;(SEQ ID NO: 34; Cla29) or(II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion; or (ii) a pharmaceutical formulation which comprises a pharmaceutically acceptable carrier or diluent and a polypeptide, or a pharmaceutically acceptable salt thereof, which is up to 30 amino acids in length and comprises:
(I) the amino acid sequence:(a)GGYKAAVRPTMLE,(SEQ ID NO: 35; Cla35)(b)AEVYQKLKSLTKK,(SEQ ID NO: 31; Cla16)(c)VAITYASRAQGAE,(SEQ ID NO: 32; Cla25)(d)GHHFKERGTGSLVIT,(SEQ ID NO: 33; Cla26)or(e)ANYTQTKTVSIRL;(SEQ ID NO: 34; Cla29) or(II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion. |
